| 35.00 Real-Time Quote |  -0.15 / -0.43%Today’s Change | 19.03 Today|||52-Week Range 39.00 | +51.06% Year-to-Date |
| SGEN's Adcetris under FDA Review - Analyst Blog May 16 / Zacks.com |
| Previous close | 35.15 |
| Today’s open | 34.89 |
| Day’s range | 33.70 - 35.55 |
| Volume | 455,088 |
| Average volume (3 months) | 798,998 |
| Market cap | $4.3B |
| Dividend yield | -- |
| Earnings growth (last year) | +65.67% |
| Earnings growth (this year) | -78.85% |
| Earnings growth (next 5 years) | +96.00% |
| Revenue growth (last year) | +122.43% |
| P/E ratio | NM |
| Price/Sales | 12.95 |
| Price/Book | 18.61 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALKSAlkermes Plc | +0.37 | +1.17% |
| IDXXIDEXX Laboratories I... | +1.27 | +1.52% |
| ENDPEndo Health Solution... | +0.44 | +1.31% |
| SLXPSalix Pharmaceutical... | -0.12 | -0.20% |
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | -$0.19 |
| Annual revenue (last year) | $210.8M |
| Annual profit (last year) | -$53.8M |
| Net profit margin | -25.51% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Clay B. Siegall, PhD |
Chief Operating Officer & Secretary Eric L. Dobmeier |
Corporate headquarters Bothell, Washington |
.
